Reaction

Mean Cell Volume Increased reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,534 reports · 83 co-occurring drugs

As of the last recalculation, Mean Cell Volume Increased appears in 2,534 FAERS reports alongside 83 co-occurring drug terms. The strongest observed disproportionality signal is NIRAPARIB (PRR 34.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Niraparib	90	34.5	34.6
Dimenhydrinate	37	28.9	29.0
Ribociclib	100	27.1	27.1
Letrozole	163	23.2	23.2
Clozapine	300	22.1	22.2
Letrozole Tablets	123	22.0	22.1
Alemtuzumab	50	21.6	21.7
Fulvestrant	82	21.0	21.1
Rucaparib	22	20.6	20.7
Eculizumab	121	19.2	19.2
Palbociclib	203	18.9	19.0
Sodium Bicarbonate	52	18.7	18.8
Sodium Bicarbonate Injection,	52	18.7	18.8
Amphotericin B	27	17.9	17.9
Valganciclovir	38	16.8	16.8
Valganciclovir Hydrochloride	38	16.8	16.8
Cimetidine	16	13.7	13.7
Dalteparin Sodium	16	12.5	12.5
Anastrozole Tablets	32	12.4	12.4
Tamsulosin Hydrochloride	30	12.2	12.2
Hydroxyurea	30	11.8	11.8
Standardized Senna Concentrate	17	11.2	11.2
Torsemide	42	10.6	10.6
Febuxostat Tablets 40 Mg	13	10.5	10.6
Febuxostat Tablets 80 Mg	13	10.5	10.6
Anastrozole	46	10.5	10.5
Goserelin	17	10.5	10.5
Ravulizumab	17	10.4	10.4
Candesartan Cilexetil	32	10.1	10.1
Lithium Carbonate	20	9.7	9.8
Darbepoetin Alfa	62	9.7	9.7
Chlorthalidone	13	9.2	9.2
Zoledronic Acid	42	8.7	8.7
Doxazosin Mesylate	37	8.5	8.5
Mycophenolic Acid	30	7.8	7.8
Cyanocobalamin	30	7.6	7.6
Methoxy Polyethylene Glycol-Epoetin Beta	10	7.5	7.5
Enoxaparin Sodium	49	7.1	7.1
Tafamidis	10	7.0	7.0
Trimethoprim	10	7.0	7.0
Exemestane	18	6.9	6.9
Deferasirox	22	6.9	6.9
Ado-Trastuzumab Emtansine	7	6.8	6.8
Thiamine Hydrochloride, Riboflavin 5 Phosphate Sodium, Dexpanthenol And Niacinamide	25	6.8	6.8
Erythropoietin	17	6.8	6.8
Doxazosin	22	6.5	6.5
Terazosin Hydrochloride	7	6.5	6.5
Insulin Glulisine	8	6.5	6.5
Umeclidinium	7	6.4	6.4
Febuxostat	13	6.4	6.4
Imatinib Mesylate	21	6.2	6.2
Pazopanib Hydrochloride	20	6.1	6.1
Tretinoin	6	6.1	6.1
Cladribine	7	6.0	6.0
Olaparib	15	5.9	5.9
Ropinirole	11	5.9	5.9
Asfotase Alfa	7	5.8	5.8
Bevacizumab	84	5.7	5.7
Dutasteride	5	5.1	5.1
Minoxidil Foam 5% (Womens)	20	5.0	5.0
Avapritinib	7	4.8	4.8
Eltrombopag Olamine	13	4.6	4.7
Instalax Polyethylene Glycol 3350	7	4.6	4.6
Polyethylene Glycol 400	7	4.5	4.5
Pertuzumab	14	4.2	4.2
Benralizumab	10	4.1	4.1
Tolvaptan	7	4.0	4.0
Ruxolitinib	34	3.9	3.9
Granisetron	5	3.9	3.9
Alpelisib	4	3.8	3.8
Minoxidil	20	3.7	3.7
Romosozumab-Aqqg	6	3.6	3.6
Trastuzumab	30	3.6	3.6
Ifosfamide	9	3.4	3.5
Pemetrexed	8	3.1	3.1
Denosumab	72	3.0	3.0
Fingolimod Hcl	29	2.8	2.8
Lutetium Lu 177 Vipivotide Tetraxetan	4	2.5	2.5
Carfilzomib	8	2.3	2.3
Dalfampridine	19	2.2	2.2
Somatropin	18	2.0	2.0
Lifitegrast	4	2.0	2.0
Relugolix	4	1.4	1.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.